PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
9.51%
Revenue growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.04%. Joel Greenblatt would investigate if growth quality matches quantity.
10.25%
Cost growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.48%. Jim Chanos would check for structural cost disadvantages.
7.27%
Growth of 7.27% versus flat Drug Manufacturers - Specialty & Generic gross profit. Walter Schloss would verify quality.
-2.04%
Margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive position.
-29.11%
R&D reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive implications.
6.96%
G&A change of 6.96% versus flat Drug Manufacturers - Specialty & Generic overhead. Walter Schloss would verify efficiency.
9.07%
Marketing expense change of 9.07% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
78.03%
Other expenses change of 78.03% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify efficiency.
4.97%
Operating expenses change of 4.97% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify control.
8.29%
Total costs growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.45%. Jim Chanos would check for waste.
-12.30%
Interest expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
2.48%
D&A growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.05%. Jim Chanos would check for overinvestment.
-17.69%
EBITDA decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
50.86%
Margin change of 50.86% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
-21.53%
Operating income decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
-10.98%
Operating margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
45.19%
Other expenses change of 45.19% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify control.
-1.98%
Pre-tax income decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate causes.
6.87%
Margin change of 6.87% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
-146.53%
Tax expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
12.27%
Income change of 12.27% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
19.89%
Margin change of 19.89% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
16.96%
EPS change of 16.96% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
16.96%
Diluted EPS change of 16.96% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
5.73%
Share count reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.02%. Jim Chanos would check for issues.
5.73%
Diluted share reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos would check for issues.